State Street’s Faeth Therapeutics FTH Stock Holding History

State Street’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,289	Closed	-$10.2K	–	4315
2025 Q1	$10.2K	Hold	1,289	–	–	﹤0.01%	4253
2024 Q4	$12.6K	Hold	1,289	–	–	﹤0.01%	4267
2024 Q3	$15.4K	Hold	1,289	–	–	﹤0.01%	4242
2024 Q2	$16K	Hold	1,289	–	–	﹤0.01%	4293
2024 Q1	$27.1K	Hold	1,289	–	–	﹤0.01%	4255
2023 Q4	$17.8K	Hold	1,289	–	–	﹤0.01%	4355
2023 Q3	$19.3K	Hold	1,289	–	–	﹤0.01%	4444
2023 Q2	$29.4K	Hold	1,289	–	–	﹤0.01%	4535
2023 Q1	$38.7K	Hold	1,289	–	–	﹤0.01%	4567
2022 Q4	$38.4K	Hold	1,289	–	–	﹤0.01%	4617
2022 Q3	$40K	Hold	1,289	–	–	﹤0.01%	4705
2022 Q2	$59K	Sell	1,289 -9,990	-89%	-$374K	﹤0.01%	4692
2022 Q1	$521K	Buy	11,279 +764	+7%	+$60.8K	﹤0.01%	4028
2021 Q4	$1.22M	Buy	10,515 +2,113	+25%	+$316K	﹤0.01%	3766
2021 Q3	$1.77M	Buy	8,402 +3,402	+68%	+$619K	﹤0.01%	3641
2021 Q2	$976K	Buy	5,000 +2,061	+70%	+$509K	﹤0.01%	3673
2021 Q1	$854K	Buy	+2,939	New	+$984K	﹤0.01%	3654

Other funds holding FTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State Street's FTH Position: Q2 2025 in Review

State Street sold out of Faeth Therapeutics (FTH) in Q2 2025, closing a stake of 1,289 shares — an estimated $10.2K sold.

State Street first reported a position in FTH in Q1 2021 and held it in 17 quarters. The position peaked at $1.77M in Q3 2021. 10 funds tracked by Wall St. Rank hold FTH as of Q2 2025.

State Street reported no remaining Faeth Therapeutics position as of Q2 2025 after selling out during the quarter.
State Street sold 1,289 Faeth Therapeutics shares in Q2 2025, an estimated $10.2K.
State Street first reported a position in Faeth Therapeutics in Q1 2021 and held it in 17 quarters.
State Street's Faeth Therapeutics position peaked at $1.77M in Q3 2021.
10 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2025.

Based on State Street's 13F filing for Q2 2025, filed 14 Aug 2025.